{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:41:11Z","timestamp":1784432471551,"version":"3.55.0"},"reference-count":84,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25038","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T22:07:51Z","timestamp":1764281271000},"page":"225-237","source":"Crossref","is-referenced-by-count":1,"title":["Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma"],"prefix":"10.3960","volume":"65","author":[{"given":"Tomotaka","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Gandhi UH, Cornell RF, Lakshman A et al.<\/i> Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33: 2266-2275.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Mateos MV, Weisel K, De Stefano V et al.<\/i> LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022; 36: 1371-1376.","DOI":"10.1038\/s41375-022-01531-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hatzoglou A, Roussel J, Bourgeade MF et al.<\/i> TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 2000; 165: 1322-1330.","DOI":"10.4049\/jimmunol.165.3.1322"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020; 13: 125.","DOI":"10.1186\/s13045-020-00962-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Yang M, Hase H, Legarda-Addison D et al.<\/i> B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol. 2005; 175: 2814-2824.","DOI":"10.4049\/jimmunol.175.5.2814"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Carpenter RO, Evbuomwan MO, Pittaluga S et al.<\/i> B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013; 19: 2048-2060.","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Munshi NC, Anderson LD Jr, Shah N et al.<\/i> Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384: 705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Berdeja JG, Madduri D, Usmani SZ et al.<\/i> Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398: 314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Martin T, Usmani SZ, Berdeja JG et al.<\/i> Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023; 41: 1265-1274.","DOI":"10.1200\/JCO.22.00842"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Goel U, Zanwar S, Cowan AJ et al.<\/i> Ciltacabtagene Autoleucel for the Treatment of Relapsed\/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy. Cancer Manag Res. 2025; 17: 357-372.","DOI":"10.2147\/CMAR.S510408"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Hansen DK, Peres LC, Dima D et al.<\/i> Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma. J Clin Oncol. 2025; 43: 1597-1609.","DOI":"10.1200\/JCO-24-01730"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Jagannath S, Martin TG, Lin Y et al.<\/i> Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma. J Clin Oncol. 2025; 43: 2766-2771.","DOI":"10.1200\/JCO.2025.43.16_suppl.7507"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Rodriguez-Otero P, Ailawadhi S, Arnulf B et al.<\/i> Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023; 388: 1002-1014.","DOI":"10.1056\/NEJMoa2213614"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 San-Miguel J, Dhakal B, Yong K et al.<\/i> Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023; 389: 335-347.","DOI":"10.1056\/NEJMoa2303379"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Ailawadhi S, Arnulf B, Patel K et al.<\/i> Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024; 144: 2389-2401.","DOI":"10.1182\/blood.2024024582"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hansen DK, Sidana S, Peres LC et al.<\/i> Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023; 41: 2087-2097.","DOI":"10.1200\/JCO.22.01365"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Lesokhin AM, Tomasson MH, Arnulf B et al.<\/i> Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023; 29: 2259-2267.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Moreau P, Garfall AL, van de Donk NWCJ et al.<\/i> Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387: 495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Tomasson MH, Iida S, Niesvizky R et al.<\/i> Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. HemaSphere. 2024; 8: e136.","DOI":"10.1002\/hem3.136"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Garfall AL, Nooka AK, van de Donk NWCJ et al.<\/i> Long-Term Follow-Up From the Phase 1\/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024; 24: S548.","DOI":"10.1016\/S2152-2650(24)01666-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Tan CR, Asoori S, Huang CY et al.<\/i> Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 2025; 15: 53.","DOI":"10.1038\/s41408-025-01259-z"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Malard F, Bobin A, Labopin M et al.<\/i> Elranatamab monotherapy in the real-world setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood Cancer J. 2024; 14: 219.","DOI":"10.1038\/s41408-024-01200-w"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Costa BA, Ortiz RJ, Lesokhin AM, Richter J. Soluble B-cell maturation antigen in multiple myeloma. Am J Hematol. 2024; 99: 727-738.","DOI":"10.1002\/ajh.27225"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Lee H, Durante M, Skerget S et al.<\/i> Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood. 2024; 144: 2637-2651.","DOI":"10.1182\/blood.2024026212"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Chen H, Yu T, Lin L et al.<\/i> \u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022; 12: 118.","DOI":"10.1038\/s41408-022-00716-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Br\u00e4uner-Osborne H, Jensen AA, Sheppard PO et al.<\/i> Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta. 2001; 1518: 237-248.","DOI":"10.1016\/S0167-4781(01)00197-X"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K et al.<\/i> GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024; 14: 24.","DOI":"10.1038\/s41408-023-00966-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Verkleij CPM, Broekmans MEC, van Duin M et al.<\/i> Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021; 5: 2196-2215.","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Smith EL, Harrington K, Staehr M et al.<\/i> GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019; 11: eaau7746.","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Zhang M, Wei G, Zhou L et al.<\/i> GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023; 10: e107-e116.","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Bal S, Anderson LD Jr, Nadeem O et al.<\/i> Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed\/Refractory (RR) Multiple Myeloma (MM). Blood. 2024; 922.","DOI":"10.1182\/blood-2024-201356"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Chari A, Minnema MC, Berdeja JG et al.<\/i> Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022; 387: 2232-2244.","DOI":"10.1056\/NEJMoa2204591"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Chari A, Touzeau C, Schinke C et al.<\/i> Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025; 12: e269-e281.","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Merz M, Dima D, Hashmi H et al.<\/i> Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J. 2024; 14: 214.","DOI":"10.1038\/s41408-024-01197-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Labanca C, Martino EA, Vigna E et al.<\/i> Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions. Eur J Haematol. 2025; 114: 386-399.","DOI":"10.1111\/ejh.14353"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Lee DW, Gardner R, Porter DL et al.<\/i> Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124: 188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Markouli M, Ullah F, Unlu S et al.<\/i> Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management. Curr Oncol. 2023; 30: 6330-6352.","DOI":"10.3390\/curroncol30070467"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Liang X, Wang Y, Luo B et al.<\/i> Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J Immunother Cancer. 2024; 12: e010064.","DOI":"10.1136\/jitc-2024-010064"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Ludwig H, Terpos E, van de Donk N et al.<\/i> Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023; 24: e255-e269.","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Haydu JE, Abramson JS. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Adv. 2024; 8: 4700-4710.","DOI":"10.1182\/bloodadvances.2021004535"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Lee DW, Santomasso BD, Locke FL et al.<\/i> ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019; 25: 625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Kennedy VE, Wong C, Huang CY et al.<\/i> Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021; 5: 5344-5348.","DOI":"10.1182\/bloodadvances.2021005020"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Yang Y, Peng H, Wang J, Li F. New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol. 2024; 13: 110.","DOI":"10.1186\/s40164-024-00573-9"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Gust J, Hay KA, Hanafi LA et al.<\/i> Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017; 7: 1404-1419.","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Cohen AD, Parekh S, Santomasso BD et al.<\/i> Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022; 12: 32.","DOI":"10.1038\/s41408-022-00629-1"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Mauget M, Lemercier S, Quelven Q et al.<\/i> Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity. Blood Adv. 2024; 8: 2491-2498.","DOI":"10.1182\/bloodadvances.2023011669"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Santomasso BD, Nastoupil LJ, Adkins S et al.<\/i> Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021; 39: 3978-3992.","DOI":"10.1200\/JCO.21.01992"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Van Oekelen O, Aleman A, Upadhyaya B et al.<\/i> Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021; 27: 2099-2103.","DOI":"10.1038\/s41591-021-01564-7"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Raje N, Berdeja J, Lin Y et al.<\/i> Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380: 1726-1737.","DOI":"10.1056\/NEJMoa1817226"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Rejeski K, Subklewe M, Aljurf M et al.<\/i> Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023; 142: 865-877.","DOI":"10.1182\/blood.2023020578"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Mancuso K, Talarico M, Manzato E et al.<\/i> T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS. Cancers (Basel). 2025; 17: 1514.","DOI":"10.3390\/cancers17091514"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Lejeune M, K\u00f6se MC, Duray E et al.<\/i> Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol. 2020; 11: 762.","DOI":"10.3389\/fimmu.2020.00762"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Li\u00e9vin R, Di Blasi R, Morin F et al.<\/i> Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transplant. 2022; 57: 431-439.","DOI":"10.1038\/s41409-021-01526-0"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Ma S, Li H, Zhou D et al.<\/i> Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Cytotherapy. 2023; 25: 653-658.","DOI":"10.1016\/j.jcyt.2023.01.011"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Cao M, Han S, Qiu Y et al.<\/i> Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T-cell therapy. Hematol Oncol. 2023; 41: 933-941.","DOI":"10.1002\/hon.3188"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Ma S, Wang Y, Qi K et al.<\/i> Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia. Cancer Immunol Immunother. 2024; 73: 104.","DOI":"10.1007\/s00262-024-03661-1"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Drillet G, Lhomme F, De Guibert S, Manson G, Houot R. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. Blood Adv. 2023; 7: 537-540.","DOI":"10.1182\/bloodadvances.2022008066"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Mohan M, Szabo A, Patwari A et al.<\/i> Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024; 59: 647-652.","DOI":"10.1038\/s41409-024-02233-2"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Cordas Dos Santos DM, Tix T, Shouval R et al.<\/i> A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024; 30: 2667-2678.","DOI":"10.1038\/s41591-024-03084-6"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Reynolds G, Cliff ERS, Mohyuddin GR et al.<\/i> Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023; 7: 5898-5903.","DOI":"10.1182\/bloodadvances.2023010539"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Yee AJ. Improving outcomes with anti-BCMA bispecific antibodies with attention to infection. Blood Cancer J. 2024; 14: 110.","DOI":"10.1038\/s41408-024-01091-x"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Hammons L, Szabo A, Janardan A et al.<\/i> The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024; 109: 906-914.","DOI":"10.3324\/haematol.2023.283590"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 O\u2019Connor BP, Raman VS, Erickson LD et al.<\/i> BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004; 199: 91-98.","DOI":"10.1084\/jem.20031330"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Nath K, Shekarkhand T, Nemirovsky D et al.<\/i> Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024; 14: 88.","DOI":"10.1038\/s41408-024-01043-5"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Lancman G, Parsa K, Kotlarz K et al.<\/i> IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023; 4: 440-451.","DOI":"10.1158\/2643-3230.BCD-23-0049"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Mohan M, Szabo A, Cheruvalath H et al.<\/i> Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J. 2025; 15: 74.","DOI":"10.1038\/s41408-025-01282-0"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Raje N, Anderson K, Einsele H et al.<\/i> Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023; 13: 116.","DOI":"10.1038\/s41408-023-00879-7"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Frerichs KA, Verkleij CPM, Mateos MV et al.<\/i> Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024; 8: 194-206.","DOI":"10.1182\/bloodadvances.2023011658"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Wolter N, Jassat W, Walaza S et al.<\/i> Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022; 399: 437-446.","DOI":"10.1016\/S0140-6736(22)00017-4"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Iuliano AD, Brunkard JM, Boehmer TK et al.<\/i> Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. 2022; 71: 146-152.","DOI":"10.15585\/mmwr.mm7104e4"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Van Oekelen O, Gleason CR, Agte S et al.<\/i> Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021; 39: 1028-1030.","DOI":"10.1016\/j.ccell.2021.06.014"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Suzuki T, Kusumoto S, Kamezaki Y et al.<\/i> Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia. Cancer Med. 2023; 12: 13135-13144.","DOI":"10.1002\/cam4.5996"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Hensley MK, Bain WG, Jacobs J et al.<\/i> Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clin Infect Dis. 2021; 73: e815-e821.","DOI":"10.1093\/cid\/ciab072"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Harrison SJ, Touzeau C, Kint N et al.<\/i> CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. N Engl J Med. 2025; 392: 677-685.","DOI":"10.1056\/NEJMoa2309728"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Mohan M, Van Oekelen O, Akhtar OS, Cohen A, Parekh S. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2024; 44: e432204.","DOI":"10.1200\/EDBK_432204"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Facon T, Dimopoulos MA, Meuleman N et al.<\/i> A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020; 34: 224-233.","DOI":"10.1038\/s41375-019-0539-0"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Kalariya NM, Hildebrandt MAT, Hansen DK et al.<\/i> Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024; 8: 4679-4688.","DOI":"10.1182\/bloodadvances.2024013540"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Adegbite B, Tan CR, Shekarkhand T et al.<\/i> Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed\/Refractory Multiple Myeloma. Blood Adv. 2025; 9: 4016-4022.","DOI":"10.1182\/bloodadvances.2025015973"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Costa LJ, Banerjee R, Mian H et al.<\/i> International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025; 39: 543-554.","DOI":"10.1038\/s41375-024-02482-6"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Ferreri CJ, Hildebrandt MAT, Hashmi H et al.<\/i> Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023; 13: 117.","DOI":"10.1038\/s41408-023-00886-8"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Riedhammer C, Bassermann F, Besemer B et al.<\/i> Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024; 38: 365-371.","DOI":"10.1038\/s41375-024-02154-5"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Trudel S, Cohen AD, Krishnan AY et al.<\/i> Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase 1 study. Blood. 2021; 138: 157.","DOI":"10.1182\/blood-2021-147983"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Zhou X, Rasche L, Kort\u00fcm KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023; 108: 958-968.","DOI":"10.3324\/haematol.2020.266841"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Cohen YC, Magen H, Gatt M et al.<\/i> Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2025; 392: 138-149.","DOI":"10.1056\/NEJMoa2406536"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25038\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:41:51Z","timestamp":1766810511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25038\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25038","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25038"}}